Grants Search Results

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. T-cell acute lymphoblastic leukemia is a deadly pediatric cancer that requires the use of highly toxic treatment. Doctors still do not know the mechanisms that lead to development of this type of leukemia. This award will train a medical student to perform experiments to identify novel targets for treatment and to help us understand the mechanisms that regulate activities of genes in T-cell leukemia.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Diffuse large B-cell lymphoma (DLBCL) makes up 10-20% of pediatric non-Hodgkin lymphomas. Although its prognosis is improving, it requires up to six months of intensive chemotherapy. Abnormal lymphocytes in DLBCL have high energy demands, so if we could exhaust their energy source, we could arrest abnormal B cell proliferation. This project aims to develop novel, targeted therapy, by depleting energy reserve for B cells, in treating childhood blood cancers.

This grant funds a student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. B cell acute lymphoblastic leukemia is the most common pediatric cancer. The most deadly subtype of this disease has high levels of the CRLF2 protein. Leukemia cells of this type can be killed when treated with high doses of a naturally occurring molecule in the body. This molecule shuts down cancer causing signals produced by CRLF2. This award will provide resources for a medical student to perform experiments to help us understand the mechanisms that this molecule uses to exerts its anti-leukemia effects so that it can be developed as a new treatment for high-risk leukemia.

This grant funds an undergraduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Diffuse intrinsic pontine glioma (DIPG) is an aggressive pediatric cancer with 10% overall survival 2 years from diagnosis. K27M mutations within histone H3 are the hallmark of DIPG. Panobinostat, a drug targeting epigenetic changes, has shown some promise in DIPG by multiple groups. These researchers' genomic analysis of DIPG cell lines shows that the cancer may be driven by LIN28. DFMO (a-difluoromethylornithine) decreases LIN28 protein levels in neuroblastoma and may be effective in treating DIPG. Therefore, the hypothesis is that co-treatment of DIPG with DFMO and panobinostat will result in increased cell death in DIPG and be an option for patients.

This grant funds a graduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Neuroblastoma (NB) is an early childhood cancer for which more effective therapies are urgently needed. Immunotherapy has been promising for blood cancers, but in solid tumors like NB, immune cells must compete with tumors for limited nutrients to sustain their function. In NB tumors, these researchers found a high frequency of a type of tumor-killing T cell with unique functional properties that may effectively shrink tumors and improve patient survival. The student is assisting in activating these cells in neuroblastoma tumor models and investigate their cellular properties, with the goal of providing a foundation for more informed immunotherapy of NB and other solid tumors.

This grant funds two students to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Project 1: There is tremendous excitement surrounding immune checkpoint inhibitor therapies. However, debate continues regarding whether pediatric cancers can benefit from such approaches, as immune checkpoint expressions are often variable and low on pediatric tumors. The student will investigate molecular signaling crosstalk, thereby providing new molecular targets for immune checkpoint blockade for childhood cancers. Project 2: Osteosarcoma (OS) is the most common malignant primary bone cancer in the pediatric and adolescent population, with about 20% of these patients presenting with pulmonary metastasis at diagnosis, while about 30% develop lung metastasis (Lung OS) after therapy initiation, accounting for most of the OS-related mortality. The SBF summer fellow will investigate the how integrin signaling associated with this.

This grant funds an undergraduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. In this summer project in the Ruggero lab, the student will learn and employ cutting edge biological techniques to identify proteins that drive medulloblastoma, focusing on specific proteins whose abundance is regulated by MYC genes.

This grant funds an undergraduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. More than 80% of children with cancer before the age of 20 years will survive beyond 5 years from diagnosis. The exposure to chemotherapy causes both short-term as well as long-term health issues in these individuals. Exercise interventions in adults with cancer demonstrate significant benefits in health, however, there are no studies examining the effects in pediatric, adolescent and young adult cancer survivors. This study will determine if a one-on-one supervised exercise program or exercise intervention personalized for adolescent and young adult (AYA) cancer survivors (15 and 29 years age) will significantly improve chemotherapy-induced health issues.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Brain tumors are the second most common childhood malignancy. Magnetic resonance imaging (MRI) is the gold-standard for detecting brain tumors. This project aims to establish novel physiological MRI protocols for non-invasive characterization of the immune and inflammatory milieu of pediatric brain tumors following radiation and immunotherapies in models.

This grant funds an undergraduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Ewing Sarcoma (ES) is an aggressive pediatric cancer. The disease has the worst prognosis when metastases are present, however mechanisms promoting its spread are not clear. These researchers have discovered a new mode of ES spread – migration along nerves. The data indicates that this process is stimulated by a protein released from these nerves – neuropeptide Y (NPY). The student is helping to identify molecules present in ES that recognize NPY and promote their invasion along the nerves, as well as test strategies preventing this effect. If successful, this study may impact ES patients by preventing tumor dissemination.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Neuroblastoma is an often-deadly malignant childhood cancer. Research in the DeClerck lab has shown that non-cancerous stromal support cells in neuroblastoma tumors play an important role in the malignant behavior of the tumor by communicating between each other. A newly-recognized method for cell communication is via little vesicles called exosomes. These are released from one cell type and are captured by other cell types in the tumor and can affect tumor malignancy and resistance to therapy. In this project, the student is examining communication through such exosome vesicles between stromal cells and neuroblastoma tumor cells.

Unlike many other pediatric cancers, osteosarcoma has many abnormalities found on genetic analysis of the tumor itself. Dr. Sweet Cordero and colleagues hypothesize that some of these abnormalities could be used to predict what treatment might work best for each specific osteosarcoma patient. For example, many osteosarcomas have genetic alterations that block their ability to "repair" their DNA using specific pathways. One of these defective pathways is called the "homologous repair" pathway and another is called the "alternative lengthening of chromosomes" pathway. The inability of osteosarcoma tumors to repair their DNA using these pathways may make them susceptible to specific drugs. However, it is very likely that these drugs will need to be used in combination and not alone. A key need to advance osteosarcoma patient care is to define and use appropriate model systems to test drugs before using them in patients. This project is combining both preclinical studies in PDX models and a clinical trial to develop new ways to treat osteosarcoma patients with the goal being to improve survival for patients with relapsed and metastatic disease.

This multi-year grant is named for and funded by the Battle Osteosarcoma Hero Fund inspired by and established in honor of Charlotte, Dylan, Tyler and all OsteoWarriors. Led by parents, its mission is to raise funds for promising osteosarcoma precision oncology research to improve treatment options and outcomes for kids battling osteosarcoma.

Therapeutic access to pediatric solid tumors, especially in the context of metastatic disease, remains a tremendous challenge. Dr Daugaard and his team are developing new ways of targeting pediatric solid tumors by exploiting distinct changes to proteins expressed on the surface of tumor cells and in the tumor microenvironment. The St. Baldrick's Robert J. Arceci Innovation Award is given in honor of the late Dr. Robert Arceci. A pioneer in the field, this award reflects Dr. Arceci's values including creativity, collaboration, and commitment to early- to mid-career scientists.

Dr. Shlien is working to define the key molecular landmarks of aggressive childhood cancers. Understanding how these lethal tumors arise will lead to better treatment and surveillance. This will impact the management of these young patients, and improve the precision of cancer care. The St. Baldrick's Robert J. Arceci Innovation Award is given in honor of the late Dr. Robert Arceci. A pioneer in the field, this award reflects Dr. Arceci's values including creativity, collaboration, and commitment to early- to mid-career scientists.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. This year it is estimated that 800 children will be diagnosed with osteosarcoma (bone cancer). It is thought that sex hormones play a role in the onset of the disease, as more boys than girls get osteosarcoma and the cancer develops at the time of puberty. We hypothesize that a key molecule in estrogen signaling, that is crucial for normal bone, is turned off in osteosarcomas, preventing those cells from being normal bone. The student is helping to understand the molecular mechanisms of estrogen silencing in osteosarcomas.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Pilocytic astrocytoma is the most common brain tumor that occurs in children. Though it only rarely does so, when this tumor spreads, it becomes much more difficult to treat. This student is working to understand why these tumors spread.

Through this partnership with The Kids' Cancer Project, proceeds from St. Baldrick's events in Australia fund life-saving research in Australia.

This grant supports personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a immunotherapy focused Clinical Research Associate to ensure that more kids can be treated on immunotherapy clinical trials, often their best hope for a cure.

Young adulthood is a time filled with exciting possibilities and also difficult challenges. People at this stage of life may be deciding on or attending school, selecting a career or working hard at their jobs, dating or in a relationship, and may be planning for or raising children. A cancer diagnosis does not fit into these plans and goals. Researchers are finding that the biology of the cancers in people of this age group are different, and increasing data indicates that adult patients with some cancers would benefit by being treated on what are traditionally pediatric therapies. Ochsner's Adolescent and Young Adult (AYA) Cancer and Survivor program is the first and only one of its kind in the region. The team is made up of professionals from pediatric and adult medicine. This program is designed for people between the ages of 15 and 39 years of age with cancer -newly diagnosed, actively in therapy and or cancer survivors. This grant supports a Nurse Coordinator who works with new patients in the combined AYA Cancer and Survivor Clinic, to ensure they have access to the best clinical trials for their cancer.